Navigation Links
Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322

ntrols its patented PROfusion protein design engine. Adnexus has over 100 issued and pending patent properties relating to Adnectins and PROfusion.

About Adnexus Therapeutics

Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of its broadly applicable new therapeutic class, Adnectins. Adnexus' lead product candidate, CT-322, is in Phase 1 clinical development in oncology in the United States. The company also has a pipeline of other Adnectin products in preclinical research across multiple therapeutic areas. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that uniquely enables rapid optimization of protein therapeutics. The company is funded by four leading venture capital firms: Atlas Venture, Flagship Ventures, Polaris Venture Partners, and Venrock Associates.

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

Adnectin(TM), Adnexus(TM) Therapeutics and PROfusion(TM) are trademarks of Adnexus(TM) Therapeutics, Inc. Adnexus(SM) Therapeutics is a service mark of Adnexus(TM) Therapeutics.

For more information, please visit www.adnexustx.com

Contact

Corporate Contacts
Adnexus Therapeutics, Inc.
Katrine Bosley, 781-891-3745
Vice President Business Development
pr@adnexustx.com
or
Media Contacts

'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

Post Your Comments:
(Date:11/30/2009).../ -- Reportlinker.com announces that a new market ..., Inflammatory Disorders: Therapies That Suppres...w.reportlinker.com/p0165600/Inflammatory-Disorders...ponse.html ,, The human immune system can go a...ing an exaggerated response to a foreign substance...
(Date:11/30/2009)... Jocelyn Rapelyea, Associate Director of Breast Im...sity Medical Center in Washington, D.C., demonstra...ific Gamma Imaging (BSGI) can be localized utilizi...l, as for pre-operative localization today at the ...h America (RSNA). ,, BSGI was conducted using a...
(Date:11/30/2009)...- Minimally-invasive procedures are increasingly r... oncology, cardiology and women,s health applicati...tion expected to reach $600 million by 2015, clini...mally-invasive procedures, including shorter patie...ter patient throughput. ,, (Logo: http://www...
Breaking Medicine Technology:Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 2Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 3Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 4Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 5Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 3Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 4Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 5Lexington Health Care Names New Chief Executive Officer 51899 1Lexington Health Care Names New Chief Executive Officer 51899 2Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 1Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 2Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 3Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 4PAL Health Technologies Wins State Level Prestigious Employer of the Year Award 51895 1PAL Health Technologies Wins State Level Prestigious Employer of the Year Award 51895 2
...ults of Roche and Ipsen,s First Once-Weekly Human ...iation Meeting -, NUTLEY, N.J., June 10 Roche an...poglutide (R1583) has been shown to provide,signif...oss after only,eight weeks of treatment(1,2) with ...try into Phase III. Taspoglutide, originating from...
...estigational Diabetes Therapy Also Improved Glucos... Taken Twice a Day, SAN FRANCISCO, June 9 Amylin...and Company (NYSE: LLY ), and Alkermes, Inc.,(Nas...k open-label clinical,study that showed the durabl... release formulation of exenatide. Patients taking...
Other Medicine Technology:Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 2Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 3Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 4Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 5Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9
(Date:11/30/2009)...s in animals , , MONDAY, Nov. 30 (Heal...that stem cells from transplanted human-derived um...heart disorders. , Scientists already know tha...st of different kinds of cells in the laboratory, ... Seoul, Korea, co-author of one of the studies, sa...
(Date:11/30/2009)...wire/ -- Kemin Foods, L.C. ("Kemin") and OmniActiv...Technologies, Ltd. ("OmniActive") have reached an ...agree that Kemin,s US Patent No. 5,382,714 ("the ,...cation and Recrystallization of Lutein from Saponi...reissues of that patent are valid and enforceable....
(Date:11/30/2009)...PRNewswire/ -- During this time of year, people be...oved one with Alzheimer,s disease or other form of...truggle with appropriate gift items. ,, Brookd...f senior living residences in the nation, includin...ggestions. ,, A listening device with recordin...
(Date:11/30/2009)... and Europa Uomo, the European,advocacy movement ...d into an,affiliated partnership as part of their...ient awareness in Europe with regards to urologica...ecretary-General of the EAU: "Thanks to this uniqu...in access to the latest information on,optimum su...
(Date:11/30/2009)...ched a series of clinical trials in order to asses... approach involves the application of personalised...rom the patient him or herself and designed to com...frequent malignant tumours. The new therapy is adm...the standard, first-line treatment involving surgi...
Breaking Medicine News(10 mins):Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6
...y hospital's inability to activate emergency power...ddle of a cataract surgery was awarded over Rs one... "It had taken about 15-20 minutes of crucial ...," observed the Consumer Disputes Redressal Forum ...
..., spread of infectious disease and food security u...ry in order to acquire the proper balance between ...phy professor of Kansas State University has used ...in uses remote sensing, in combination with other ...
...Toronto General Hospital, researchers have discove...ion //of specific repair cells from the bone marro...le it has long been known that bone marrow cells h... stem cells in repairing a damaged heart, restorin...
...a good 14 years has revealed that regular exercise...e body weight has an impact in cutting down the ri...uthor of the study, said "Even though erectile pro...." Obesity also affects sexual health, he said. ...
...f BARACLUDE? (entecavir) for the treatment of chro...proval by the Drug Controller General of India. ...atment of chronic hepatitis B virus infection in a... active disease. BARACLUDE? is an oral antiv...
...management training center, not only training Indi...tries//. The MV Hospital for Diabetes and Diabetes...zation’s collaborating centre for diabetes researc...e center is currently coaching a Pakistani physici...
Other Medicine News:Health News:Ecological Changes affects human health, food security 2Health News:Bone Marrow Cells Aid In Heart Repair 2Health News:Bone Marrow Cells Aid In Heart Repair 3Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
Cushing Burr
Doro J-Arm Retractor System
Molt 9
Langenbeck Periosteal Elevators
Medicine Products: